 |
|
|
| |
REAL-LIFE TREATMENT RATES FOR HEPATOCELLULAR CARCINOMA IN HIV-INFECTED PATIENTS
|
| |
| |
"A high proportion of HIV-infected patients diagnosed of HCC did not receive therapy or receive less effective treatment as recommended by its BCLC stage.....Eighty-four (32.5%) out of 258 patients who were potentially candidates to therapy did not receive therapy or receive treatment less effective as indicated by BCLC (Table 1). The proportion of patients receiving no/less effective therapy varied according to the BCLC stage. Thus, it was 25%, 34.6% and 43% in patients at BCLC stage 0/A, B and C, respectively (p<0.0001) (Table 1). Forty-one (43.6%) out of 94 cases diagnosed prior to 2010 and potentially candidates to HCC treatment received no/less effective therapy than recommended, while this occurred in 45 (27.4%) out of 164 cases diagnosed from 2010 (p=0.03). Conversely, the proportion of HCC cases diagnosed at stage 0/A increased in the second period (36 out of 128 [28%] vs. 85 out of 190 [45%]; p < 0.001)."
Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
N Merchante1, F Rodríguez-Arrondo2, E Merino3, B Revollo4, S Ibarra5, M García Deltoro6, F Tellez7, J Portu8, A Romero-Palacios9, JA Pineda1.
1Hospital Universitario de Valme, Sevilla; 2Hospital Universitario de Donostia, San Sebastian; 3Hospital General Universitario de Alicante; 4Hospital Universitario German Trias i Pujol, Badalona; 5Hospital Universitario de Basurto, Vizcaya; 6Hospital General de Valencia, Valencia; 7Hospital de La Línea, Cadiz; 8Hospital de Txagorritxu, Vitoria; 9Hospital de Puerto Real, Cadiz. Spain.
On behalf of Grupo para el Estudio de las Hepatitis Víricas (GEHEP) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
|
| |
|
|
|
|
|
